EquitySector - HealthcareVery High Risk
Regular
NAV (15-Oct-25)
Returns (Since Inception)
Fund Size
₹3,933 Cr
Expense Ratio
1.93%
ISIN
INF200K01446
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
31 Dec 2004
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+2.00%
— (Cat Avg.)
3 Years
+25.49%
+22.74% (Cat Avg.)
5 Years
+19.49%
+17.95% (Cat Avg.)
10 Years
+10.95%
+12.65% (Cat Avg.)
Since Inception
+15.39%
— (Cat Avg.)
Equity | ₹3,790.18 Cr | 96.36% |
Others | ₹143.08 Cr | 3.64% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹430.46 Cr | 10.94% |
Divi's Laboratories Ltd | Equity | ₹250.34 Cr | 6.36% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹222.94 Cr | 5.67% |
Cipla Ltd | Equity | ₹180.4 Cr | 4.59% |
Lupin Ltd | Equity | ₹160.55 Cr | 4.08% |
Lonza Group Ltd ADR | Equity | ₹159.76 Cr | 4.06% |
Treps | Cash - Repurchase Agreement | ₹151.45 Cr | 3.85% |
Fortis Healthcare Ltd | Equity | ₹145.47 Cr | 3.70% |
Torrent Pharmaceuticals Ltd | Equity | ₹144.13 Cr | 3.66% |
Gland Pharma Ltd | Equity | ₹139.41 Cr | 3.54% |
Mankind Pharma Ltd | Equity | ₹131.53 Cr | 3.34% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹126.46 Cr | 3.22% |
Jupiter Life Line Hospitals Ltd | Equity | ₹126.04 Cr | 3.20% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹122.53 Cr | 3.12% |
Concord Biotech Ltd | Equity | ₹118.63 Cr | 3.02% |
Acutaas Chemicals Ltd | Equity | ₹118.6 Cr | 3.02% |
Laurus Labs Ltd | Equity | ₹117.85 Cr | 3.00% |
Abbott India Ltd | Equity | ₹117.16 Cr | 2.98% |
Poly Medicure Ltd | Equity | ₹116.89 Cr | 2.97% |
Biocon Ltd | Equity | ₹109.12 Cr | 2.77% |
Alkem Laboratories Ltd | Equity | ₹108.5 Cr | 2.76% |
Cohance Lifesciences Ltd | Equity | ₹105.49 Cr | 2.68% |
Aether Industries Ltd | Equity | ₹105.27 Cr | 2.68% |
Anthem Biosciences Ltd | Equity | ₹91.34 Cr | 2.32% |
Aurobindo Pharma Ltd | Equity | ₹75.87 Cr | 1.93% |
Vijaya Diagnostic Centre Ltd | Equity | ₹60 Cr | 1.53% |
Pfizer Ltd | Equity | ₹50.36 Cr | 1.28% |
Rainbow Childrens Medicare Ltd | Equity | ₹50.02 Cr | 1.27% |
Gufic Biosciences Ltd | Equity | ₹35.45 Cr | 0.90% |
Sanofi Consumer Healthcare India Ltd | Equity | ₹35.4 Cr | 0.90% |
Medplus Health Services Ltd | Equity | ₹34.21 Cr | 0.87% |
Net Receivable / Payable | Cash - Collateral | ₹-11.35 Cr | 0.29% |
India (Republic of) | Bond - Short-term Government Bills | ₹2.98 Cr | 0.08% |
Large Cap Stocks
38.65%
Mid Cap Stocks
17.14%
Small Cap Stocks
34.19%
AAA
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹3,566.31 Cr | 90.67% |
Basic Materials | ₹223.88 Cr | 5.69% |
Standard Deviation
This fund
14.07%
Cat. avg.
15.99%
Lower the better
Sharpe Ratio
This fund
1.18
Cat. avg.
0.92
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.64
Higher the better
Since June 2011
ISIN INF200K01446 | Expense Ratio 1.93% | Exit Load No Charges | Fund Size ₹3,933 Cr | Age 20 years 9 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Total AUM
₹11,89,494 Cr
Address
C-38 & 39, G Block, Bandra Kurla Complex, Mumbai, 400 051
Your principal amount will be at Very High Risk
EquitySector - HealthcareVery High Risk
Regular
NAV (15-Oct-25)
Returns (Since Inception)
Fund Size
₹3,933 Cr
Expense Ratio
1.93%
ISIN
INF200K01446
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
31 Dec 2004
Your principal amount will be at Very High Risk
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+2.00%
— (Cat Avg.)
3 Years
+25.49%
+22.74% (Cat Avg.)
5 Years
+19.49%
+17.95% (Cat Avg.)
10 Years
+10.95%
+12.65% (Cat Avg.)
Since Inception
+15.39%
— (Cat Avg.)
Equity | ₹3,790.18 Cr | 96.36% |
Others | ₹143.08 Cr | 3.64% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹430.46 Cr | 10.94% |
Divi's Laboratories Ltd | Equity | ₹250.34 Cr | 6.36% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹222.94 Cr | 5.67% |
Cipla Ltd | Equity | ₹180.4 Cr | 4.59% |
Lupin Ltd | Equity | ₹160.55 Cr | 4.08% |
Lonza Group Ltd ADR | Equity | ₹159.76 Cr | 4.06% |
Treps | Cash - Repurchase Agreement | ₹151.45 Cr | 3.85% |
Fortis Healthcare Ltd | Equity | ₹145.47 Cr | 3.70% |
Torrent Pharmaceuticals Ltd | Equity | ₹144.13 Cr | 3.66% |
Gland Pharma Ltd | Equity | ₹139.41 Cr | 3.54% |
Mankind Pharma Ltd | Equity | ₹131.53 Cr | 3.34% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹126.46 Cr | 3.22% |
Jupiter Life Line Hospitals Ltd | Equity | ₹126.04 Cr | 3.20% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹122.53 Cr | 3.12% |
Concord Biotech Ltd | Equity | ₹118.63 Cr | 3.02% |
Acutaas Chemicals Ltd | Equity | ₹118.6 Cr | 3.02% |
Laurus Labs Ltd | Equity | ₹117.85 Cr | 3.00% |
Abbott India Ltd | Equity | ₹117.16 Cr | 2.98% |
Poly Medicure Ltd | Equity | ₹116.89 Cr | 2.97% |
Biocon Ltd | Equity | ₹109.12 Cr | 2.77% |
Alkem Laboratories Ltd | Equity | ₹108.5 Cr | 2.76% |
Cohance Lifesciences Ltd | Equity | ₹105.49 Cr | 2.68% |
Aether Industries Ltd | Equity | ₹105.27 Cr | 2.68% |
Anthem Biosciences Ltd | Equity | ₹91.34 Cr | 2.32% |
Aurobindo Pharma Ltd | Equity | ₹75.87 Cr | 1.93% |
Vijaya Diagnostic Centre Ltd | Equity | ₹60 Cr | 1.53% |
Pfizer Ltd | Equity | ₹50.36 Cr | 1.28% |
Rainbow Childrens Medicare Ltd | Equity | ₹50.02 Cr | 1.27% |
Gufic Biosciences Ltd | Equity | ₹35.45 Cr | 0.90% |
Sanofi Consumer Healthcare India Ltd | Equity | ₹35.4 Cr | 0.90% |
Medplus Health Services Ltd | Equity | ₹34.21 Cr | 0.87% |
Net Receivable / Payable | Cash - Collateral | ₹-11.35 Cr | 0.29% |
India (Republic of) | Bond - Short-term Government Bills | ₹2.98 Cr | 0.08% |
Large Cap Stocks
38.65%
Mid Cap Stocks
17.14%
Small Cap Stocks
34.19%
AAA
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹3,566.31 Cr | 90.67% |
Basic Materials | ₹223.88 Cr | 5.69% |
Standard Deviation
This fund
14.07%
Cat. avg.
15.99%
Lower the better
Sharpe Ratio
This fund
1.18
Cat. avg.
0.92
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.64
Higher the better
Since June 2011
ISIN INF200K01446 | Expense Ratio 1.93% | Exit Load No Charges | Fund Size ₹3,933 Cr | Age 20 years 9 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Total AUM
₹11,89,494 Cr
Address
C-38 & 39, G Block, Bandra Kurla Complex, Mumbai, 400 051
Get your portfolio reviewed by experts
Download Wealth Monitor App
Track and monitor all
your investments